久久久久免费_精品国产乱码久久久久久久软件_欧美一区亚洲一区_国产一区二区三区高清在线观看_欧美日在线观看_成人网av

 美國艾爾建 Allergan  
 Allergan公司從2002年7月1日起成為專業的藥品公司，在中國更名為愛力根公司，主要從事眼科藥物，神經科藥物以及其他領域的藥物研發。其總部位于美國加州的歐文市, 產品行銷超過100個國家。 1948年,Allergan公司從洛杉磯一間小藥房發展成立起來, 1970年擴展為全球性公司。 Allergan公司從成立之日起,憑借其卓越的技術和創新的精神, 不斷加大對科學研究的投入, 在美國總部和法國、英國、意大利和日本都設有研究中心,共有科研人員780名,其中超過130名具有博士或博士后學位，在R&D(研究及開發)方面投入的巨額資金超過了全部銷售額的12%以上，從而不斷推出創新性的優質藥品。 公司的口號是 Eye Care we care (細心呵護您的雙眼)。公司的宗旨是取之“取之于社會，回報予社會” 主要產品：抗青光眼藥：阿法根，貝他根；抗菌素：艾若；類固醇類抗炎藥：百力特，氟米龍；非甾體類抗炎藥：安賀拉；人工淚液：瀟萊威，瑞新；復合抗菌抗炎類：帕利百；抗充血類：歐斯啉

Allergan is a global, technology-driven multi-specialty health care company pursuing therapeutic advances to help patients live life to their fullest potential. In making this commitment, we work to develop an unparalleled level of insight into patients' wants and needs — and into the priorities and concerns of the medical specialists who treat them. To this end, we employ more than 50 percent of our work force in either research and development (R&D) or sales, ensuring our efforts are focused on innovation and our customers.

Allergan's flagship franchises in eye care, neurosciences, medical dermatology and urologics are structured under the company's pharmaceutical business portfolio, Allergan Pharmaceuticals. This portfolio offers specialty physicians and their patients a wide range of treatments to help preserve and protect sight, reduce physical disability and enhance quality of life.

With the acquisition of Inamed Corporation in 2006, Allergan added breast aesthetics and dermal fillers to its business portfolio to create a world-leading medical aesthetics franchise. The acquisition also gained Allergan a leading product portfolio in obesity intervention that offers minimally invasive devices to help patients achieve sustained weight loss and reduce health risks associated with obesity. All of these products are now represented within the Allergan Medical corporate division.

With specialty product lines focused on high-growth markets, Allergan represents a new multi-specialty health care model for the future, where diversification and focus live together to offer physicians and patients best-in-class treatments and a robust pipeline for continuous innovation. Bolstered by an integrated R&D organization and global infrastructure, characteristics of some of the industry's largest pharmaceutical companies, Allergan also maintains a lean and efficient operation with solid growth prospects, like many smaller and more specialized organizations in the health care field. Allergan is large enough to command sufficient resources to address significant patient needs yet small enough for nimble execution. As we look to the future, we will continue to follow our R&D technologies into additional specialty areas and build a leadership presence of relevance to the doctors and patients we serve.